Turnstone Biologics Inc.

30 articles with Turnstone Biologics Inc.

• Turnstone Biologics Enters Cooperative Research and Development Agreement with the National Cancer Institute to Study TIL Therapy in Combination with Viral Immunotherapy

  11/29/2022

  Turnstone Biologics Corp today announced that it has entered into a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), to evaluate the generation of tumor-reactive T-cells, which form the basis of Turnstone’s tumor-infiltrating lymphocyte platform.

• Turnstone Biologics Announces FDA Clearance of IND for TIDAL-01, a Next-Generation TIL Therapy for Solid Tumors

  10/31/2022

  Turnstone Biologics Corp, a clinical-stage biotechnology company developing next-generation immunotherapies to treat and cure solid tumors, announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug for Turnstone’s lead selected tumor-infiltrating lymphocyte therapy program, TIDAL-01.

• 

  Boehringer, Evotec and bioMérieux Recognize AMR Threat and More Deals

  7/6/2022

  Boehringer, Evotec and bioMérieux found Aurobac to combat antimicrobial resistance, Turnstone and Moffitt Expand TIL Collab, Skyhawk to gain potential $2B from Sanofi RNA splicing deal.

• Turnstone Biologics and Moffitt Cancer Center Announce Strategic Alliance to Advance Next-Generation TIL Therapies for Solid Tumors

  7/6/2022

  Turnstone Biologics Corp. and Moffitt Cancer Center announced the formation of a broad strategic alliance, deepening their existing multi-year research collaboration.

• Turnstone Biologics Announces TIL Therapy Research Collaboration with the University of Montreal Hospital Research Centre

  4/25/2022

  Turnstone Biologics Corp. announced a research collaboration with the University of Montreal Hospital Research Centre [Centre de recherche du Centre hospitalier de l’Université de Montréal, ], to drive advancements in TIL therapy using tumor-reactive T-cells.

•  Turnstone Biologics Announces Executive Leadership Appointments

  4/19/2022

  Turnstone Biologics Corp. announced the appointments of Venkat Ramanan, Ph.D., as Chief Financial Officer, and P. Joseph Campisi Jr., J.D., M.B.A., as General Counsel.

• Turnstone Biologics Expands Scientific Advisory Board with Appointments of Dr. James Mulé and Dr. Eric Tran

  12/15/2021

  Turnstone Biologics Corp., a clinical-stage biotechnology company pioneering the development of cancer immunotherapies, announced the expansion of its Scientific Advisory Board with the appointments of two leaders in the cell therapy field, James Mulé, IPh.D., and Eric Tran, Ph.D.

• Turnstone Biologics Announces Research Collaboration with Moffitt Cancer Center to Advance Novel TIL Immunotherapies for Solid Tumor Indications

  11/29/2021

  Turnstone Biologics Corp., a clinical-stage biotechnology company pioneering the development of cancer immunotherapies, announced that it has entered into a strategic multi-year research collaboration with Moffitt Cancer Center for pre-clinical development of investigational tumor-infiltrating lymphocyte therapies.

• 

  Turnstone and Moffitt Cancer Center Team Up on TILs

  11/29/2021

  New York-based Turnstone Biologics announced it is partnering with the Moffitt Cancer Center to develop tumor-infiltrating lymphocyte (TIL) therapies.
• 

  Money on the Move: July 21 – 27, 2021

  7/28/2021

  A quick overview of life science companies scooping up some summer spending money this week.

• Turnstone Biologics Raises $80 Million Series D Financing

  7/21/2021

  Turnstone Biologics Corp., a clinical-stage biotechnology company pioneering the development of cancer immunotherapies, announced the successful completion of an $80 million Series D financing co-led by PFM Health Sciences and Point72.

• Turnstone Biologics Appoints Stewart Abbot, Ph.D., as Chief Scientific Officer

  6/29/2021

  Dr Abbot’s appointment further strengthens Turnstone’s senior leadership team, adding depth and expertise in immune cell therapy

• Turnstone Biologics Announces Executive Leadership Promotions and Board Appointment

  5/7/2021

  Turnstone Biologics Corp., a clinical-stage biotechnology company focused on the development of cancer immunotherapies, today announced the promotions of José Manuel Otero, Ph.D., to Chief Technology Officer, and Saryah Azmat to Chief Business Officer. Turnstone also announced that Mike Burgess, MB. ChB., Ph.D., will transition from President of R&D to Executive Chairman of R&D and be appointed to the Turnstone Board of Directors

• SIGA Announces Collaboration with Turnstone Biologics

  3/2/2020

  SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that it entered into a collaboration with Turnstone Biologics to provide TPOXX ® (tecovirimat) in connection with Turnstone’s proprietary SKV vaccinia oncolytic immunotherapy platform.

• 

  BioSpace Movers & Shakers, Jan. 10

  1/10/2020

  Pharma and biotech companies bolster their executive leadership teams and boards of directors with this week's appointments.

• Turnstone Appoints Saryah Azmat as Senior Vice President of Business Development and Corporate Strategy

  1/8/2020

  Ms. Azmat will lead identification, evaluation and execution of new business development opportunities and development of the company’s corporate growth strategy.

• Turnstone Biologics Announces Global Collaboration and License Agreement with Takeda to Develop Novel Viral Immunotherapies

  12/19/2019

  Turnstone and Takeda to co-develop and co-commercialize RIVAL-01, the lead candidate from Turnstone’s proprietary vaccinia virus platform, with a 50:50 global profit share

• 

  Interview: As Gene and Cell Therapies Grow, Reimbursement Model Needs to Change

  5/8/2019

  Although the advent of cell and gene therapies is revolutionizing medicine, it is arguable that the therapies that have been approved to date in this area aren’t living up to expectations.

• Turnstone Biologics Unveils Novel Vaccinia Oncolytic Viral Immunotherapy Platform

  11/30/2018

  Groundbreaking Research by Oncolytic Virus Pioneer Dr. John Bell will be Presented at the American Association for Cancer Research Tumor Immunology and Immunotherapy Meeting

• Turnstone Biologics and the La Jolla Institute for Allergy and Immunology Enter into Strategic Collaboration for Personalized Neoantigen Immunotherapies

  9/4/2018

  ​Turnstone Obtaining License to Neoantigen Identification Methodology Developed by the La Jolla Institute.